Relationship between sST2 levels and prognosis in patients with pulmonary arterial hypertension

Sahin A., KAYA H., GÜL İ.

ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, vol.11, pp.172-177, 2020 (ESCI) identifier


Aim: Soluble Suppression of Tumorigenicity-2 (sST2) was approved for non-invasive risk assessment and its prognostic benefits were monitored in some heterogeneous pulmonary hypertension cohorts. In this study, we aimed to evaluate the relationship of sST2 use with clinical deterioration and survival in pulmonary arterial hypertension (PAH) patients.